Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference22 articles.
1. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia;Roth;N Engl J Med,2012
2. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy;McKenney;J Am Coll Cardiol,2012
3. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
4. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial;Roth;Int J Cardiol,2014
5. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher;Ginsberg;Cardiovasc Drugs Ther,2016
Cited by 81 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events;Pharmacology & Therapeutics;2023-10
2. Assessment of the global and national market for lipid modifying agents: retrospective and innovation;Сибирский научный медицинский журнал;2023-08-29
3. The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods;Molecules;2023-08-07
4. Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events;Frontiers in Cardiovascular Medicine;2023-06-26
5. The evolving landscape of PCSK9 inhibition in cancer;European Journal of Pharmacology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3